Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 4;30(9):8172-8185.
doi: 10.3390/curroncol30090593.

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2023

Essa Al-Mansor  1 , Meghan Mahoney  2 , Maxime Chenard-Poirier  3 , Ravi Ramjeesingh  4 , Vimoj Nair  1 , Erin Kennedy  5 , Gordon Locke  1 , Stephen Welch  6 , Scott Berry  7 , Felix Couture  3 , Elena Elimova  8 , Aaron Pollett  5 , Aamer Mahmud  7 , Brooke Wilson  7 , Dawn Armstrong  2 , Conrad Falkson  7 , Timothy Asmis  1 , Michael Vickers  1 , Rachel Goodwin  1
Affiliations

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2023

Essa Al-Mansor et al. Curr Oncol. .

Abstract

The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2023 was held in Quebec City, Quebec 2-4 February 2023. The purpose of the conference was to develop consensus statements on emerging and evolving treatment paradigms. Participants included Canadian medical oncologists, radiation oncologists, pathologists and surgical oncologists from across Ontario, Quebec, and the Atlantic provinces. Consensus statements were developed following rapid review presentations and discussion of available literature. The recommendations proposed here represent the consensus opinions of physicians involved in the care of patients with gastrointestinal malignancies who participated in this meeting.

Keywords: chemotherapy; colon cancer; gastro-esophageal cancer; guidelines; hepatocellular carcinoma; immunotherapy; pancreatic cancer; radiation therapy; rectal cancer; surgery.

PubMed Disclaimer

Conflict of interest statement

Bruce Colwell—none. Conrad Falkson—none. Brooke Wilson—none. Dawn Armstrong—none. Rachel Goodwin—advisory ad board or speaker work for Merck, Taiho, Amgen, Eaisi, Roche, Astra Zeneca, BMS (enrolls multiple patients on clinical trials and is a PI on local and Canadian clinical trials). Michael Vickers—none. Aamer Mahmud—none. Mustaphe Tehfe lists the following: BMS, advisory board and invited speaker; Incyte, advisory board, Merck, advisory board, pfizer, advisory board, Taiho, advisory board and invited speaker, Amgen, local PI, Bioentech, local PI, BMS, local PI, Novartis, local PI, Pfizer, research grant, Taiho, research grant. Timothy Asmis is a consultant for Novartis, AZ, Bayer, Merck, BMS, Taiho, Medison and Roche.

References

    1. Tissue-Agnostic Cancer Therapy: DNA Mismatch Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Solid Tumors—UpToDate. [(accessed on 15 February 2023)]. Available online: https://www.uptodate.com/contents/tissue-agnostic-cancer-therapy-dna-mis....
    1. Brahmer J.R., Drake C.G., Wollner I., Powderly J.D., Picus J., Sharfman W.H., Stankevich E., Pons A., Salay T.M., McMiller T.L., et al. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. J. Clin. Oncol. 2010;28:3167–3175. doi: 10.1200/JCO.2009.26.7609. - DOI - PMC - PubMed
    1. André T., Shiu K.-K., Kim T.W., Jensen B.V., Jensen L.H., Punt C., Smith D., Garcia-Carbonero R., Benavides M., Gibbs P., et al. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer. N. Engl. J. Med. 2020;383:2207–2218. doi: 10.1056/NEJMoa2017699. - DOI - PubMed
    1. Lenz H.-J., Van Cutsem E., Luisa Limon M., Wong K.Y.M., Hendlisz A., Aglietta M., García-Alfonso P., Neyns B., Luppi G., Cardin D.B., et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J. Clin. Oncol. 2022;40:161–170. doi: 10.1200/JCO.21.01015. - DOI - PubMed
    1. Le D.T., Kim T.W., Van Cutsem E., Geva R., Jäger D., Hara H., Burge M., O’Neil B., Kavan P., Yoshino T., et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J. Clin. Oncol. 2020;38:11–19. doi: 10.1200/JCO.19.02107. - DOI - PMC - PubMed

Publication types

LinkOut - more resources